Fed Governor Adriana Kugler to resign
On Tuesday, Evercore ISI reiterated its Outperform rating on Illumina stock (NASDAQ:ILMN) with a steady price target of $160.00, positioning it between the current analyst range of $90 to $190. According to InvestingPro data, the company generated revenue of $4.37 billion in the last twelve months, with an EBITDA of $701 million. The firm’s analysts highlighted the appointment of Keith Meister, founder of the activist investment firm Corvex Management, to Illumina’s board of directors. Meister’s previous experience includes a seven-year tenure as the Principal Executive Officer and Vice Chairman of the Board at Icahn Enterprises (NASDAQ:IEP).
Illumina has faced several challenges at the outset of FY25, including funding reductions from the National Institutes of Health (NIH), a prohibition on instrument sales in China, and competitive threats such as Roche’s potential entry into the Next (LON:NXT) Generation Sequencing (NGS) market. These issues have contributed to a significant downturn, with InvestingPro data showing a year-to-date decline of 34.13% and a six-month return of -30.23%. For detailed analysis of Illumina’s challenges and opportunities, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
The analysts believe that while some of Illumina’s challenges, like NIH funding cuts and the situation in China, depend on time for resolution, the company can take charge of other aspects, such as market communication. The addition of Meister to an already strong board that includes C-suite executives from companies like Intuitive Surgical (NASDAQ:ISRG), Edwards Lifesciences (NYSE:EW), and Hologic (NASDAQ:HOLX), is seen as a positive move that should help improve Wall Street’s perception and messaging.
A central short-term debate among investors revolves around whether the current $4.50 earnings per share (EPS) represents a bottom line for the stock, with some concern over additional risks. The upcoming first-quarter earnings call, scheduled for April 25, 2025, is anticipated to clarify assumptions regarding this EPS floor. InvestingPro analysis reveals that six analysts have recently revised their earnings downwards for the upcoming period, though net income is expected to grow this year.
Looking beyond immediate concerns, Evercore ISI suggests that Illumina could more effectively communicate the opportunities within its pipeline. This includes ventures into areas like 5 base sequencing, automated library prep, proteomics, spatial genomics, and single-cell analysis. The analysts note that the company’s goal for high single-digit percentage topline growth by FY27 currently assumes a successful transition to the NovaSeq X platform and does not fully account for potential revenue from new pipeline developments. The company operates with a moderate level of debt and maintains a healthy current ratio of 1.78, according to InvestingPro metrics.
In other recent news, Illumina has announced several significant developments affecting its board and executive team. The company revealed that Keith Meister, an activist investor from Corvex Management, will join the board, and Scott Gottlieb will assume the role of chairman. These changes follow the resignation of Stephen MacMillan as chair and are part of broader shifts influenced by interest from investors like Carl Icahn and Roche. In addition, Illumina’s Chief Information Officer, Carissa Rollins, will retire in April 2025, marking a notable transition in the company’s leadership.
On the financial front, Illumina’s recent guidance update prompted RBC Capital Markets to reduce its stock price target to $128, while maintaining an Outperform rating. This revision is influenced by uncertainties in the China market, where Illumina faces export restrictions imposed by the China Ministry of Commerce. In response, Illumina adjusted its 2025 earnings per share guidance to approximately $4.50 and launched a cost reduction program to save around $100 million in 2025. Canaccord Genuity also lowered its price target for Illumina to $115, maintaining a Hold rating, citing the challenges in the Chinese market as a key factor.
Despite these hurdles, Illumina remains focused on achieving high single-digit revenue growth by 2027 through its comprehensive portfolio of technologies. Analysts from both Canaccord Genuity and RBC Capital Markets acknowledge the company’s strategic efforts but emphasize the need for tangible financial improvements. Investors will be closely watching how Illumina navigates these developments and adapts its strategies to maintain its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.